- Home
- IMAB vs ZURA Comparison
IMAB vs ZURA Comparison
Compare IMAB & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- ZURA
- Stock Information
- Founded
- IMAB 2014
- ZURA 2022
- Country
- IMAB United States
- ZURA United States
- Employees
- IMAB N/A
- ZURA N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMAB Health Care
- ZURA Health Care
- Exchange
- IMAB Nasdaq
- ZURA Nasdaq
- Market Cap
- IMAB 73.9M
- ZURA 76.6M
- IPO Year
- IMAB 2020
- ZURA N/A
- Fundamental
- Price
- IMAB $0.89
- ZURA $1.20
- Analyst Decision
- IMAB Strong Buy
- ZURA Buy
- Analyst Count
- IMAB 2
- ZURA 7
- Target Price
- IMAB $5.50
- ZURA $14.67
- AVG Volume (30 Days)
- IMAB 220.3K
- ZURA 381.0K
- Earning Date
- IMAB 04-03-2025
- ZURA 05-12-2025
- Dividend Yield
- IMAB N/A
- ZURA N/A
- EPS Growth
- IMAB N/A
- ZURA N/A
- EPS
- IMAB N/A
- ZURA N/A
- Revenue
- IMAB N/A
- ZURA N/A
- Revenue This Year
- IMAB N/A
- ZURA N/A
- Revenue Next Year
- IMAB N/A
- ZURA N/A
- P/E Ratio
- IMAB N/A
- ZURA N/A
- Revenue Growth
- IMAB N/A
- ZURA N/A
- 52 Week Low
- IMAB $0.60
- ZURA $0.97
- 52 Week High
- IMAB $2.00
- ZURA $6.35
- Technical
- Relative Strength Index (RSI)
- IMAB 54.14
- ZURA 44.19
- Support Level
- IMAB $0.85
- ZURA $1.18
- Resistance Level
- IMAB $0.97
- ZURA $1.55
- Average True Range (ATR)
- IMAB 0.06
- ZURA 0.15
- MACD
- IMAB 0.01
- ZURA -0.01
- Stochastic Oscillator
- IMAB 56.71
- ZURA 21.97
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.